المؤلفون: Pascual Izquierdo, Cristina, Mingot Castellano, María Eva, Kerguelen Fuentes, Ana E., García-Arroba Peinado, José, Cid, Joan, Moraima Jimenez, Maria, Valcarcel, David, Gómez Seguí, Inés, de la Rubia, Javier, Martin, Paz, Goterris, Rosa, Hernández, Luis, Tallón, Inmaculada, Varea, Sara, Fernández, Marta, García Muñoz, Nadia, Vara, Míriam, Fernández Zarzoso, Miguel, García Candel, Faustino, Paciello, María Liz, García García, Irene, Zalba, Saioa, Campuzano, Verónica, Gala, José María, Vidán Estévez, Julia, Moreno Jiménez, Gemma, López Lorenzo, José Luis, González Arias, Elena, Freiría, Carmen, Solé, María, Ávila Idrovo, Laura Francisca, Hernández Castellet, José Carlos, Cruz, Naylen, Lavilla, Esperanza, Pérez Montaña, Albert, Atucha, Jon Ander, Moreno Beltrán, María Esperanza, Moreno Macías, Juán Ramón, Salinas, Ramón, del Rio Garma, Julio

المصدر: Blood Advances. Vol. 6, nº 24, December 2022, pp. 6219 - 6227

مصطلحات موضوعية: caplacizumab, prednisone, rituximab

الوصف: Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P < .05) and less refractoriness (4.5% vs 14.1%; P < .05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P < .05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P < .001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX. ; 9 páginas

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10498/29789Test

الإتاحة: https://doi.org/10.1182/bloodadvances.2022008028Test
http://hdl.handle.net/10498/29789Test

المؤلفون: Mingot-Castellano, María-Eva, García-Candel, Faustino, Martínez-Nieto, Jorge, García-Arroba, José, de la Rubia-Comos, Javier, Gómez-Seguí, Inés, Paciello-Coronel, María-Liz, Valcárcel-Ferreiras, David, Jiménez, Moraima, Cid, Joan, Lozano, Miquel, García-Gala, José-María, Angós-Vazquez, Sonia, Vara-Pampliega, Miriam, Guerra-Domínguez, Luisa, Ávila-Idrobo, Laura-Francisca, Oliva-Hernandez, Ana, Zalba-Marcos, Saioa, Tallón-Ruiz, Inmaculada, Ortega-Sánchez, Sandra, Goterris-Viciedo, Rosa, Moreno-Jiménez, Gemma, Domínguez-Acosta, Lourdes, Araiz-Ramírez, María, Hernández-Mateos, Luis, Flores-Ballesteros, Elena, del Río-Garma, Julio, Pascual-Izquierdo, Cristina, Abio Calvete, Mariola, Albert, Albert, Alberto López García, Alberto, Alegre, Adrian, Alkorta Eizagirre, Aitziber, Alonso Escobar, María Nieves, Alonso Madrigal, Cristina, Amunarriz, Cristina, Antelo Caamaño, María Luisa, Arbona Castaño, Cristina, Ballester Ruiz, Maria Carmen, Ballina Martín, Belén, Berberana Fernández de Murias, Margarita, Berrueco Moreno, Ruben, Bueno, Jose Luis, Calderón López, María Teresa, Chica Gullón, Esther, Cid Vidal, Joan, Contreras Barbeta, Enric, Cuéllar Pérez-Ávila, Clara, de la Rubia Comos, Javier, Del Orbe Barreto, Rafael Andres, Del Río Garma, Julio, Díaz Valdés, José R., Diaz-Ricart, Maribel, Diez Gallarreta, Zuriñe, Dueñas Hernando, Virginia, Eguia, Blanca, Escoda, Lourdes, Fernández Docampo, Marta, Fernandez Fuertes, Fernando, Fernández Muñoz, Hermogenes, Fernández Sánchez de Mora, Maria Carmen, Fernandez Zarzoso, Miguel, Fidalgo, Teresa, Flores Ballester, Elena, Fonte Feal, Cristina, Galvez, Francisco Javier, Garcia Arroba Peinado, Jose, García Candel, Faustino, Garcia Erce, Jose Antonio, García Gala, José María, Gimeno, JJ, Gómez, Delia, Gómez Seguí, Inés, Gomez Vazquez, Maria Jesus, Gonzalez, Carlos, González Fernández, Fernando Ataulfo, Gonzalez Porras, Jose Ramon, Gonzalez Rodriguez, Victoria Paz, Goterris Viciedo, Rosa, Guerra Domínguez, Luisa, Guillén García, Helga, Hernandez, Adoracion, Hernández Castellet, José Carlos, Hernandez Mohedo, Francisca, Hernandez Vazquez, Laura, Hidalgo Soto, Marta, Hong Tam, Azueg Hang, Kerguelen Fuentes, Ana Lilia, Leal Bento, Marta, Lopes, Raquel, López, Olga, López Chuliá, Francisca, Maria Jose Busto, Maria Jose, Martín Hernández, María Paz, Martinez Estefano, Elvira, Martinez Nieto, Jorge, Martinez Redondo, Consuelo, Martinez Revuelta, Eva, Medina Marrero, Laura, Mingot Castellano, María Eva, Morales Sanz, María Dolores, Moreno, Gemma, Moreno Beltrán, Mª Esperanza, Moreno Chulilla, Jose Antonio, Nistal Gil, Sara, Oliva Hernandez, Ana Yurena, Pascual, Teresa, Pascual Izquierdo, Crisina, Paumard Rodríguez, Elena, Pecos, Patricia, Peña Marcos, Francisco, Pereira Coelho, Daniela Sofia, Pérez Segura, Gloria Maria, Perez-Lopez, Olga, Prieto Pareja, Elena, Ramiro, Laia, Richart López, Luis Alberto, Rodriguez Dominguez, Maria Jesus, Rodriguez Nuñez, Antonio, Ruiz Sainz, María Elena, Saez Serrano, Isabel, Salinas Argente, Ramón, Sanchez, Maria Elena, Sanchez Anton, Piva, Sánchez Fernández, Mª Soledad, Sebastian, Elena, Simona, Gabriela, Solanich Moreno, Xabier, Soledad Casado, Soledad, Tallón, Jose David, Turcu, Violeta, Valledor Méndez, Manuel, Vidan Y Estevez, Julia, Viejo Llorente, Aurora, Bienert, Álvaro, Serrano, Alfons, Llorente, Laura, Campuzano, Verónica, Tallón, Inmaculada, Pons, Verónica, Linares, Mónica, Valles, Ana, Martínez Francés, Antonio, Freiria, Carmen, González Arias, Elena, Araujo, Enmanuel, Marco de Lucas, Fernando, López, Juan Antonio, Uribe Barrientos, Marisol, Calviño, Michael, Gómez Calafat, Montse, Marco Vera, Pascual, Fariña, Sabela, Zalba, Saioa, Monsalvo, Silvia, Escamilla, Virginia

المصدر: Blood; May 2024, Vol. 143 Issue: 18 p1807-1815, 9p

مستخلص: •There is no delay in ADAMTS13 recovery after PEX start in caplacizumab–treated patients with iTTP from the Spanish registry.•Caplacizumab allows suspending PEX earlier, thus creating the impression that there is a delay in ADAMTS13 recovery after PEX end.

المؤلفون: Pascual Izquierdo, Cristina, Mingot Castellano, María Eva, Kerguelen Fuentes, Ana E., García Arroba Peinado, José, Cid Vidal, Joan, Jimenez, Maria Moraima, Valcarcel, David, Gómez Seguí, Inés, Rubia, Javier de la, Martin, Paz, Goterris, Rosa, Hernández, Luis, Tallón, Inmaculada, Varea, Sara, Fernández, Marta, García Muñoz, Nadia, Vara, Míriam, Fernández Zarzoso, Miguel, García Candel, Faustino, Paciello, María Liz, García García, Irene, Zalba, Saioa, Campuzano, Verónica, Gala, José María, Vidán Estévez, Julia, Moreno Jiménez, Gemma, López Lorenzo, José Luis, González Arias, Elena, Freiría, Carmen, Solé, María, Ávila Idrovo, Laura Francisca, Hernández Castellet, José Carlos, Cruz, Naylen, Lavilla, Esperanza, Pérez Montaña, Albert, Atucha, Jon Ander, Moreno Beltrán, María Esperanza, Moreno Macías, Juán Ramón, Salinas, Ramón, Rio Garma, Julio del, Spanish Apheresis Group (GEA), Spanish Thrombotic Thrombocytopenic Purpura Registry (REPTT)

المصدر: Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

مصطلحات موضوعية: Rituximab, Trombosi, Assaigs clínics, Thrombosis, Clinical trials

الوصف: Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P < .05) and less refractoriness (4.5% vs 14.1%; P < .05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P < .05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P < .001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX.

وصف الملف: 9 p.; application/pdf

العلاقة: Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2022008028Test; Blood Advances, 2022, vol. 6, num. 24, p. 6219-6227; https://doi.org/10.1182/bloodadvances.2022008028Test; http://hdl.handle.net/2445/196688Test

الإتاحة: https://doi.org/10.1182/bloodadvances.2022008028Test
http://hdl.handle.net/2445/196688Test

المؤلفون: Izquierdo, Cristina Pascual, Mingot-Castellano, María Eva, Fuentes, Ana E. Kerguelen, García-Arroba Peinado, José, Cid, Joan, Jimenez, Maria Moraima, Valcarcel, David, Gómez-Seguí, Inés, de la Rubia, Javier, Martin, Paz, Goterris, Rosa, Hernández, Luis, Tallón, Inmaculada, Varea, Sara, Fernández, Marta, García-Muñoz, Nadia, Vara, Míriam, Zarzoso, Miguel Fernández, García-Candel, Faustino, Paciello, María Liz, García-García, Irene, Zalba, Saioa, Campuzano, Verónica, Gala, José María, Estévez, Julia Vidán, Jiménez, Gemma Moreno, López Lorenzo, José Luis, Arias, Elena González, Freiría, Carmen, Solé, María, Ávila Idrovo, Laura Francisca, Hernández Castellet, José Carlos, Cruz, Naylen, Lavilla, Esperanza, Pérez-Montaña, Albert, Atucha, Jon Ander, Moreno Beltrán, María Esperanza, Moreno Macías, Juán Ramón, Salinas, Ramón, del Rio-Garma, Julio

المصدر: Blood Advances; December 2022, Vol. 6 Issue: 24 p6219-6227, 9p

مستخلص: Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P < .05) and less refractoriness (4.5% vs 14.1%; P < .05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P < .05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P < .001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX.

المؤلفون: Domínguez‐Muñoz, M. Ángeles, Calderón‐Cabrera, Cristina, Morales, Rosario M., Prats, Concepción, Ruiz, Marta, Tallón, Inmaculada, Bernal, Ricardo, Pérez‐Simón, José Antonio

المصدر: Diagnostic Cytopathology ; volume 43, issue 6, page 478-481 ; ISSN 8755-1039 1097-0339

الإتاحة: https://doi.org/10.1002/dc.23203Test

المؤلفون: Martínez-Bravo, María José, Tallón, Inmaculada, Espigado, Ildefonso, Pérez-Simón, José A., Pérez-Romero, Pilar, García-Ahufinger, Irene, Aguilera, Isabel, Núñez-Roldán, Antonio

الوصف: B cell responses to minor histocompatibility antigens (mHags) have not been extensively studied after allogeneic hematopoietic stem cell transplantation (HSCT). Glutathione S-transferase T1 (GSTT1) is a drug metabolizing enzyme encoded by a single gene that is highly expressed in liver and kidney. Anti-GSTT1 antibodies have been described in the context of antibody-mediated rejection in kidney and liver transplantation, due to a mismatch between donor and recipient. The aim of the present study was to investigate the specific immune response against GSTT1 in HSCT with production of antibodies and their influence in the development of hepatic graft-versus-host-disease (GVHD). Forty patients and their respective donors were included in the study. The median follow-up time was 35.6. months (range 0.6-76. months) and a total of 349 serum samples were tested for the presence of anti-GSTT1 antibodies by ELISA test. Statistical analysis was performed by defining the GSTT1 null donor/positive recipient as mismatch compared with the other three genetic combinations regarded as GSTT1-matched. Antibodies were found in three patients within the group of null donor/positive recipient and one within the null/null group. Development of liver GVHD, particularly its acute form, was highly associated with the GSTT1-mismatch (P=0.0178) and with the presence of post-transplant anti-GSTT1 antibodies (P=0.0076). We conclude that GSTT1 could be considered as a new mHag in hepatic GVHD. The fact that three donors were parous females and the rapid production of antibodies after HSCT suggests the existence in the graft of memory B-cells specific for the GSTT1 antigen. © 2011 Elsevier B.V. ; This work was supported by grants from the Ministry of Education and Science of Spain (05/0733, 05/0374) and grants from Junta de Andalucia, Spain (PI-0332/2007, P07-CTS-02886). The work carried out at our laboratory, received support from the European Community through the regional development funding program (FEDER). ; Peer Reviewed

العلاقة: Immunology Letters 141(1): 140-144 (2011); http://hdl.handle.net/10261/68582Test

الإتاحة: https://doi.org/10.1016/j.imlet.2011.09.005Test
http://hdl.handle.net/10261/68582Test

المؤلفون: Domínguez ‐ Muñoz, M. Ángeles, Calderón ‐ Cabrera, Cristina, Morales, Rosario M., Prats, Concepción, Ruiz, Marta, Tallón, Inmaculada, Bernal, Ricardo, Pérez ‐ Simón, José Antonio, Pambuccian, Stephan

المصدر: Diagnostic Cytopathology; Jun2015, Vol. 43 Issue 6, p478-481, 4p

المؤلفون: Martínez-Bravo, María José, Tallón, Inmaculada, Espigado, Ildefonso, Urbano-Ispizua, Alvaro, Núñez-Roldán, Antonio, Aguilera, Isabel

المصدر: Blood; November 2010, Vol. 116 Issue: 21 p2323-2323, 1p

مستخلص: Abstract 2323